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ABSTRACT
Introduction: Frailty is associated with changes
in inflammation, coagulation, and possibly
platelet function. Aspirin is still prescribed for
stroke prevention in older patients with atrial
fibrillation, although not recommended by
current guidelines. In frail older people, it is
unclear whether platelet aggregability and
response to aspirin are altered. This study aims
to investigate the effects of frailty and
chronological age on platelet aggregability and
on responses to aspirin in older patients with
atrial fibrillation.
Methods: Inpatients with atrial fibrillation aged
C65 years were recruited from a tertiary referral
hospital in Sydney, Australia. Frailty was
determined using the Reported Edmonton
Frail Scale. Platelet aggregation studies were
performed using whole blood impedance
aggregometry.
Results: Data from 115 participants were
analyzed (mean age 85 ± 6 years, 41% female,
52% frail). Spearman correlation coefficients
found no significant associations of platelet
aggregation with chronological age or with
frailty score. Comparison between frail and
non-frail groups showed that there was no
impact of frailty status on aggregation assays
amongst participants who were not taking any
antiplatelet drugs. Amongst participants taking
aspirin, the frail had higher adjusted
arachidonic acid agonist (ASPI) test measures
(AU per platelet) than the non-frail (0.11 ± 0.11
vs. 0.05 ± 0.04; p = 0.04), suggesting that in
frail participants, platelet aggregation is less
responsive to aspirin than in non-frail.
Conclusions: We found no effect of
chronological age or frailty status on platelet
aggregation amongst older patients with atrial
fibrillation in this pilot study. However, frailty
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could be associated with reduced aspirin
responsiveness among older patients with
atrial fibrillation.
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INTRODUCTION
There is marked heterogeneity amongst people
aged over 65 years. Some of this may be
captured by increasing chronological age.
However, much of this variability is thought
to be due to biological age or frailty [1]. Frailty is
a state of vulnerability that carries an increased
risk of poor outcomes in older adults [1]. The
prevalence and clinical importance of frailty are
increasing with ageing of the population [1, 2].
Frailty is associated with changes in
inflammation, coagulation, and possibly
platelet function [3, 4].
Atrial fibrillation (AF) is a common cardiac
arrhythmia in older adults. The prevalence of
AF in published studies in Western countries
ranges from 0.5% to 3% in the general
population, 5–6% in people older than
65 years, and up to 5–15% among those aged
80 years or older [5–7]. Treatment of AF aims at
stroke prevention with antithrombotic therapy,
reducing symptoms with rate-control or
rhythm-control strategies, and management of
associated medical conditions [8]. According to
the current guidelines, aspirin is not
recommended for stroke prevention in AF
unless patients refuse the use of any oral
anticoagulant [9, 10]. International drug
utilization studies show that, in practice,
17–45% of older adults use aspirin for stroke
prevention in AF [11–14]. The evidence for
stroke prevention in AF with aspirin is weak
and the risk of major bleeding with aspirin is
not significantly different to that of oral
anticoagulants, especially in older people [9,
15, 16].
The efficacy of antiplatelet drugs has not
been rigorously tested in older people and older
people are generally more vulnerable to adverse
drug effects due to changes in pharmacokinetics
and pharmacodynamics associated with aging
and an increased risk of drug–drug and
drug–disease interactions in the presence of
polypharmacy and multimorbidity [17]. In
frail older people, it is unclear whether
response to antiplatelet therapies is altered.
Some studies have suggested that platelet
aggregability may increase in old age [4, 18,
19] and plasma aspirin esterase activity is
reduced in frail people [20–22]. However, there
has been no study exploring the association
between frailty and platelet aggregation.
Therefore, the aims of this study were to
investigate the effects of frailty and
chronological age on platelet aggregability and
on platelet responses to aspirin in older patients
with AF.
METHODS
A total of 302 inpatients aged C65 years with AF
at Royal North Shore Hospital, a tertiary referral
teaching hospital in Sydney, Australia, were
recruited for a study of anticoagulant utilization
and outcomes in frail and non-frail older
inpatients with AF. Of these patients, 134
participated in this sub-study on platelet
aggregation. Among these patients, 82 who
were not taking any antiplatelet drugs for at
least a week before blood samples were taken for
testing and 33 patients who were taking regular
aspirin (100 mg daily) and no other antiplatelet
agents were eligible for this analysis. Informed
consent was obtained from all participants or
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their caregivers. The study was approved by The
Northern Sydney Local Health District Human
Research Ethics Committee and The University
of Sydney Human Research Ethics Committee.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013.
Frailty was determined using the Reported
Edmonton Frail Scale [23]. This scale, which was
adapted from the Edmonton Frail Scale for use
in Australian acute inpatients, assesses nine
frailty domains: cognition, general health
status, functional independence, social
support, medication use, nutrition, mood,
continence, and reported functional
performance. With a maximum score of 18, a
score of 0–5 indicates robust, 6–7 indicates
apparently vulnerable status, 8–9 mild frailty,
10–11 moderate frailty, and 12 or higher
indicates severe frailty. The cut-off point to
identify frailty is 8 [23].
Blood was collected from the participants in
the morning from the antecubital vein into
tubes containing hirudin. Platelet aggregation
studies were performed between 30 min and 2 h
after blood was taken, using whole blood
impedance aggregometry (WBIA, Multiplate
Analyser, Roche Diagnostics). The Multiplate
Analyser measures aggregation in whole blood
samples through changes in electrical
impedance between two electrodes and has
been applied to detect platelet inhibition by
aspirin in many studies [24–29]. More details
about the test have been described elsewhere
[30, 31]. Platelet agonists used in this assay were
arachidonic acid (ASPItest) to trigger
arachidonic acid-induced platelet aggregation,
which is affected by aspirin; adenosine
diphosphate (ADPtest) to trigger ADP-induced
platelet aggregation, which is affected by
thienopyridines (e.g., clopidogrel, prasugrel,
ticlopidine); and Thrombin Receptor
Activating Peptide 6 (TRAPtest) to trigger
TRAP-6 induced platelet aggregation, which is
only affected by glycoprotein IIb/IIIa receptor
antagonists (e.g., tirofiban, abciximab,
eptifibatide). ADPtest and TRAPtest were used
as positive controls for platelet reactivity.
Platelet aggregation is defined by the area
under the aggregation-time curve, which
represents the aggregation over 6 min, and
values are reported in arbitrary aggregation
units (AU). Suggested normal ranges in
healthy blood donors as provided by the
manufacturer are 71–115 AU for the ASPItest,
57–113 AU for the ADPtest, and 84–128 AU for
the TRAPtest [32].
Analysis of the data was performed using
SPSS for Windows 20.0 (IBM Corp., Armonk,
NY, USA). Continuous variables are presented as
mean ± standard deviation, and categorical
variables as frequency and percentage. Clinical
characteristics and laboratory parameters were
compared between frailty and treatment groups
using the Mann–Whitney U test for continuous
variables, and Chi-square or Fisher’s exact test
for binary variables. Correlation of platelet
aggregation with age, frailty score, and other
variables that have previously been shown to
have an impact on platelet aggregation [33] was
assessed with Spearman correlation. Two-sided
p values \0.05 were considered significant.
Platelet function was considered separately for
each treatment regimen and by frailty status.
The platelet counts in this study showed a
marked degree of variation (mean
220 ± 95 9 109/l, median 202 9 109/l, range
30–502 9 109/l). Twenty-five patients had
platelet counts below the normal range, and,
as expected, these patients had significantly
lower AU values than patients with platelet
counts in the normal range (p\0.001).
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Spearman correlation also showed that platelet
count had a very strong association with
platelet aggregation (r = 0.59, p\0.001 for
ASPI test; r = 0.63, p\0.001 for ADP test;
r = 0.69, p\0.001 for TRAP test). Therefore,
we adjusted the test results to control for the
effect of the platelet counts and provide a purer
representation of platelet aggregability by
dividing the AU value by the platelet count,
giving a value of AU per platelet. We compared
aggregability between frail and non-frail
participants with and without aspirin
treatment based on these adjusted values.
Sensitivity analyses were also performed to
assess the robustness of the finding after
excluding those participants with platelet
counts\100 9 109/l or[400 9 109/l.
RESULTS
A total of 115 participants were included in the
study (mean age 85 ± 6 years, age range
71–97 years, 41% female, 52% frail). Among
the 82 participants who did not take any
antiplatelet therapy in the week prior to
sampling (Table 1), mean age was 84 ± 6 years
and 49% of the participants were frail.
Compared to the non-frail, frail participants
had a significantly higher score on the Charlson
Comorbidity Index, with a higher prevalence of
heart failure and renal impairment. There was
no quantitative difference in any of the
platelet-aggregation assays between frail and
non-frail participants. Spearman correlation
coefficients were performed for each test of
platelet aggregation with age, frailty score, and
other variables that may impact platelet
aggregation (Table 2). There were no
significant correlations between platelet
aggregation and any of these variables.
Among the 33 participants who were taking
aspirin, the frail (n = 20) had higher ASPI test
results than the non-frail (0.11± 0.11 AU per
platelet in the frail versus 0.05± 0.04 AU per
platelet in thenon-frail; p = 0.04), suggesting that
platelets in the frail are less responsive to aspirin
(Table 3). Representative curves from the ASPI
tests of a frail and non-frail participant are shown
in Fig. 1. Spearman correlation coefficients of the
ASPI test results with age, frailty score and other
variables found that the only significant
correlation was of the presence of a diagnosis of
heart failure with increased AU (correlation
coefficient 0.40, p = 0.02) (Table 4). Sensitivity
analyses showed that the difference between the
frail and the non-frail remained significant
amongst the participants with platelet counts
from 100–400 9 109/l (n = 26), consistent with
the analyses amongst those with platelet counts
from 30–5029 109/l (n = 33) (Table 5).
DISCUSSION
In this pilot study of older inpatients with AF,
there was no significant relationship between
platelet aggregation and chronological age. This
result is different to many previous studies in
which there was a trend towards increased
platelet aggregation with age [4, 18, 19, 33].
However, all of these studies were designed to
compare platelet aggregation between younger
groups and older groups (participant age ranged
from around 20 to 80 years old, with the cut-off
point to determine older groups usually around
60 years old). In contrast, in our study the mean
age of participants was around 84–86 years,
with an age range from 71 to 97 years.
Furthermore, unlike our study of acutely
unwell older inpatients, previous studies
demonstrating increased platelet aggregation
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with age were in healthy volunteers from the
community without a history of cardiovascular
disease. Additionally, in this study we used the
Multiplate assay—a new method to evaluate
platelet aggregation, which is different from
light transmission aggregometry that was used
in previous studies [4, 18, 19, 33].
Amongst participants not taking antiplatelet
drugs, there was no association between frailty
status, a marker of biological age, and platelet
aggregation. Amongst those taking aspirin,
there was a significant difference in platelet
aggregation to arachidonic acid (ASPI test): the
frail exhibited a degree of aspirin resistance
compared to the non-frail. The reduced
responsiveness to aspirin observed in the frail
may be partly attributed to the higher
prevalence of heart failure in the frail
Table 1 Characteristics of 82 participants not taking any antiplatelet therapy
All (n 5 82) Frail (n5 40) Non-frail (n5 42) p values
Age (years) 84.00 ± 6.08 84.98 ± 6.40 83.05 ± 5.67 0.08
Female gender 33 (40.20%) 18 (45.00%) 15 (35.70%) 0.39
Hypertension 51 (62.20%) 23 (57.50%) 28 (66.70%) 0.39
Heart failure 38 (46.30%) 24 (60.00%) 14 (33.30%) 0.02
Ischemic heart disease 35 (42.70%) 18 (45.00%) 17 (40.50%) 0.68
Diabetes mellitus type 2 15 (18.30%) 9 (22.50%) 6 (14.30%) 0.31
Dyslipidemia 25 (30.50%) 10 (25.00%) 15 (35.70%) 0.29
Peripheral vascular disease 8 (9.80%) 7 (17.50%) 1 (2.40%) 0.02
Stroke 24 (29.30%) 13 (32.50%) 11 (26.20%) 0.53
History of cancer/current cancer 22 (26.80%) 10 (25.00%) 12 (28.60%) 0.72
Female gender 37 (45.10%) 25 (62.50%) 12 (28.60%) 0.002
Reported Edmonton Frail Score 7.48 ± 2.84 9.88 ± 1.64 5.19 ± 1.55 \0.001
Charlson Comorbidity Index 3.84 ± 2.30 4.50 ± 2.10 3.21 ± 2.32 0.004
Hemoglobin (g/l) 178 ± 122 119 ± 21 125 ± 21 0.26
White cell count (9109/l) 7.43 ± 2.53 7.34 ± 2.40 7.50 ± 2.68 0.99
Platelet count (9109/l) 226 ± 92 217 ± 107 234 ± 74 0.22
Platelet aggregation (AU)
ADPtest 58 ± 26 56 ± 28 60 ± 24 0.29
ASPItest 68 ± 28 65 ± 30 70 ± 26 0.41
TRAPtest 77 ± 29 75 ± 32 80 ± 26 0.53
Adjusted platelet aggregation (AU per platelet)
ASPItest 0.31 ± 0.09 0.31 ± 0.11 0.30 ± 0.07 0.43
ADPtest 0.26 ± 0.11 0.27 ± 0.12 0.26 ± 0.10 0.95
TRAPtest 0.36 ± 0.13 0.37 ± 0.15 0.35 ± 0.11 0.81
Continuous data are presented as mean ± standard deviation or median (range). Categorical data are shown as n (%)
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participants. In participants taking aspirin, we
found a moderate positive correlation between
heart failure and arachidonic acid-induced
platelet aggregation, which means that
compared to participants without a history of
heart failure, those with heart failure tend to
have a higher on-treatment platelet
aggregation. The relationship between heart
failure and decreased aspirin effectiveness has
been reported in several studies [34, 35].
Although not comprehensively understood,
this could be explained by several mechanisms
such as increased levels of circulating
catecholamines, angiotensin II and
b-thromboglobulin, platelet factor 4,
P-selectin, and platelet-endothelial cell
adhesion molecules in patients with heart
failure [36]. The observed reduced platelet
responsiveness to aspirin in the frail supports
the current guidelines that do not recommend
aspirin for stroke prevention in AF, and raises a
question about the risk-to-benefit ratio of
aspirin prescription in older patients with AF,
which ironically is more common in the frail
[37], in whom prescribers may be more
concerned about using anticoagulants.
The study comprised a sample of very old
and frail people, who are often excluded from
studies [38]. Recently, objective measures of
frailty, including the Reported Edmonton Frail
Scale used in our study [23], have facilitated
study of the physiology and management of
frailty [1]. The physiological etiology of frailty is
still not comprehensively understood. Multiple
physiological factors are thought to be involved
in the development of frailty, including
activation of inflammation, coagulation
systems, and changes in pharmacokinetics and
pharmacodynamics [1, 3, 21, 39]. Studies
measuring individual factors in the
Table 2 Spearman correlation coefﬁcients for platelet aggregation with age, frailty scores, and other variables in 82







Age (years) 0.10 0.10 0.05
Reported Edmonton Frail Score -0.03 0.12 0.01
Charlson Comorbidity Index -0.15 0.01 0.02
Body mass index (kg/m2) 0.01 0.09 0.11
Dyslipidemia -0.18 -0.07 -0.12
Diabetes mellitus 0.10 0.19 0.14
Heart failure -0.01 0.13 0.06
Ischemic heart disease -0.06 -0.13 -0.05
History of cancer/current cancer -0.04 0.03 0.09
Female gender 0.04 0.01 0.09
Anticoagulant users (warfarin/heparin) -0.07 -0.07 -0.01
Hemoglobin (g/dl) -0.17 -0.16 -0.09
White cell count (9109/l) 0.09 0.16 -0.08
A positive correlation indicates that the variable is associated with increased platelet aggregation. All p values were[0.05
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coagulation system suggest that frailty is
associated with pro-coagulant changes such as
increased plasma fibrinogen, factor VIII,
C-reactive protein, D-dimer, and tissue
plasminogen activator (t-PA) plasma levels
[40–43]. To our knowledge, there has been no
previous study focusing on the impact of frailty
on platelet aggregation and platelet response to
antiplatelet drugs. There have only been several
studies reporting the association between frailty
and reduced activity of plasma aspirin esterase,
a hydrolysis enzyme that helps the conversion
of aspirin (acetylsalicylic acid) to salicylic and
acetic acid [20, 21].
Table 3 Characteristics of the 33 participants taking aspirin
All (n5 33) Frail (n5 20) Non-frail (n 5 13) p values
Age (years) 86.52 ± 6.90 86.60 ± 6.64 86.38 ± 7.57 0.96
Reported Edmonton Frail Score 8.03 ± 2.69 9.75 ± 1.48 5.38 ± 1.81 \0.001
Charlson 3.33 ± 2.03 3.55 ± 2.04 3.00 ± 2.04 0.52
Female gender 14 (42.40%) 6 (30.00%) 8 (61.50%) 0.07
Hypertension 22 (66.70%) 14 (70.00%) 8 (61.50%) 0.61
Heart failure 15 (45.50%) 13 (65.00%) 2 (15.40%) 0.005
Ischemic heart disease 16 (48.50%) 11 (55.00%) 5 (38.50%) 0.35
Diabetes mellitus type 2 6 (18.20%) 4 (20.00%) 2 (15.40%) 1.00
Dyslipidemia 9 (27.30%) 7 (35.00%) 2 (15.40%) 0.26
Peripheral vascular disease 5 (15.20%) 4 (20.00%) 1 (7.70%) 0.63
Stroke 9 (27.30%) 5 (25.00%) 4 (30.80%) 0.72
Cancer 7 (21.20%) 5 (25.00%) 2 (15.40%) 0.67
eGFR\60(ml/min/1.73 m2) 15 (45.50%) 7 (35.00%) 8 (61.50%) 0.14
Hemoglobin (g/l) 114 ± 19 112 ± 21 116 ± 16 0.41
White cell count (9109/l) 7.69 ± 2.89 8.11 ± 3.37 7.08 ± 1.93 0.34
Platelet count (9109/l) 205 ± 104 186 ± 100 235 ± 107 0.28
Platelet aggregation (AU)
ASPItest 15 ± 13 18 ± 15 11 ± 8 0.21
ADPtest 51 ± 31 47 ± 31 58 ± 31 0.37
TRAPtest 66 ± 34 61 ± 35 74 ± 31 0.27
Adjusted platelet aggregation (AU per platelet)
ASPItest 0.09 ± 0.09 0.11 ± 0.11 0.05 ± 0.04 0.04
ADPtest 0.25 ± 0.09 0.25 ± 0.10 0.24 ± 0.07 1.00
TRAPtest 0.35 ± 0.17 0.36 ± 0.21 0.33 ± 0.09 0.90
Continuous data are presented as mean ± SD. Categorical data are shown as n (%)
eGFR estimated glomerular ﬁltration rate
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In this study, we used the Multiplate
method to study platelet aggregation. Since
the introduction of the bleeding time test,
different methodologies have been developed
to obtain the optimal platelet function test
and to assess platelet reactivity in response to
antiplatelet drugs [44–47]. The Multiplate is a
new method for evaluating platelet
aggregation and is one of the point-of-care
assays for monitoring antiplatelet therapy [30].
It can be performed in whole blood, does not
require specifically trained laboratory
personnel, and is simple to interpret [45].
This method has been widely used in clinical
trials and is also implemented in daily practice
in catheterization laboratories, predominantly
in Europe [44]. However, it should be noted
that the correlation of this test with other
tests of platelet aggregation and with clinical
outcomes is not perfect [29, 48] and that this
test has not been validated in very old or frail
participants. The Multiplate assay provides a
reproducible measure of reduced platelet
aggregation in response to defined agonists.
However, unlike assays measuring platelet
response to very low doses of agonists, which
were used in previous studies of platelet
function in ageing [4, 18, 19, 33], the
Multiplate assay is not designed to detect
platelet hyperaggregability.
A major limitation of this study is that it was
done in the acute care setting, in which platelet
aggregation may be influenced by acute
inflammation [49]. This is a pilot study testing
the hypothesis of altered platelet aggregation
with frailty that relies on a convenience sample.
Small sample size may have limited the power
of this study to observe small changes with age
and frailty. This study sample is based on
volunteers from inpatients recruited for a
study on anticoagulant utilization.
Approximately half of the participants in that
study agreed to a blood test, so the sample may
be not representative of older inpatients with
Fig. 1 Arachidonic acid-induced platelet aggregation
(ASPItest) in participants taking aspirin. a From a
representative frail participant. b From a representative
non-frail participant. (One Multiplate test cell includes two
independent sensor units. The increase of impedance due to
the attachment of platelets to the electrodes is detected for
each sensor unit separately and transformed to arbitrary
aggregation units that are plotted against time. The
duplicate sensors work as an internal control) [24]
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AF. Furthermore, all of the participants in this
study had AF, which may be procoagulant [50].
Therefore, results should be cautiously
interpreted and generalized to older inpatients
without AF who may be prescribed aspirin for
other indications.
Table 4 Spearman correlation for platelet aggregation in response to aspirin with age, frailty score, and other variables in 33
participants taking aspirin
Variables ASPI test (AU per platelet) p values
Age (years) 0.03 0.87
Reported Edmonton Frail Score 0.19 0.29
Charlson Comorbidity Index 0.10 0.56
Body mass index (kg/m2) 0.30 0.24
Dyslipidemia 0.16 0.38
Diabetes mellitus 0.14 0.44
Heart failure 0.40 0.02
Ischemic heart disease 0.19 0.29
History of cancer/current cancer -0.17 0.34
Female gender -0.08 0.64
Anticoagulant users (warfarin/heparin) 0.20 0.26
Hemoglobin (g/dl) 0.04 0.84
White cell count (9109/l) 0.29 0.11
A positive correlation indicates that the variable is associated with increased arachidonic acid-induced platelet aggregation
(e.g., less responded to aspirin)
Table 5 Results from sensitivity analyses assessing the impact of frailty on antiplatelet responsiveness
All Frail Non-frail p values
All participants on aspirin (platelet counts 30–502 9 109/l) N = 33 N = 20 N = 13
Adjusted platelet aggregation (AU per platelet)
ASPItest 0.090 ± 0.090 0.110 ± 0.110 0.050 ± 0.035 0.036
ADPtest 0.245 ± 0.091 0.252 ± 0.104 0.241 ± 0.068 1.000
TRAPtest 0.349 ± 0.173 0.363 ± 0.213 0.327 ± 0.088 0.899
Participants with platelet counts
100–400 9 109/l
N = 26 N = 15 N = 11
Adjusted platelet aggregation (AU per platelet)
ASPItest 0.078 ± 0.056 0.096 ± 0.063 0.055 ± 0.036 0.047
ADPtest 0.241 ± 0.092 0.240 ± 0.105 0.243 ± 0.075 0.799
TRAPtest 0.329 ± 0.133 0.322 ± 0.160 0.339 ± 0.089 0.540
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CONCLUSIONS
We found no effect of chronological age or
frailty status on platelet aggregation amongst
hospitalized older patients with AF in this pilot
study. Response to aspirin is reduced in the frail
and in those with heart failure. This may have
implications for efficacy of aspirin in this
population.
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